• Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1 

      Aberg, Judith A.; Shepherd, Bronagh; Wang, Marcia; Madruga, José V.; Urbina, Fernando Mendo; Katlama, Christine; Schrader, Shannon; Eron, Joseph J.; Kumar, Princy N.; Sprinz, Eduardo; Gartland, Margaret; Chabria, Shiven; Clark, Andrew; Pierce, Amy; Lataillade, Max; Tenorio, Allan R. (2023) [Artigo de periódico]
      Introduction: Efficacy and safety of the attachment inhibitor fostemsavir + optimized background therapy (OBT) were evaluated through 48 and 96 weeks in the phase 3 BRIGHTE trial in heavily treatment-experienced (HTE) ...